BioCentury | Aug 6, 2012
Emerging Company Profile

Ascletis: Cash for China deals

While Ascletis Pharmaceuticals Co. Ltd. aspires to discover its own drugs, it is employing a two-pronged strategy that includes in-licensing clinical candidates for the Chinese market. Its first external compound comes from Alnylam Pharmaceuticals Inc....
Items per page:
1 - 1 of 1